Contributions of EndotoxinEd

Contributions by EndotoxinEd, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 15,330 edits includes activity predating the current log.

1. 08:57, 18 Jul 2026 (diff | hist) Hubei Jianxiang Bioscience 12,122 ±0 split overlong sentence
2. 10:07, 8 Jul 2026 (diff | hist) Hubei Jianxiang Bioscience 12,122 ±0 m rv promotional edit
3. 19:35, 5 Jul 2026 (diff | hist) Beyond-use date 23,171 ±0 move table to the section it supports
4. 12:35, 4 Jul 2026 (diff | hist) Tianjin Finder Chemical 11,889 ±0 m correct percentage: source reports placebo-adjusted
5. 15:47, 22 Jun 2026 (diff | hist) Tianjin Finder Chemical 11,889 ±0 tag ^{[citation needed]}
6. 18:33, 14 Jun 2026 (diff | hist) Beyond-use date 23,171 ±0 m copyedit
7. 14:03, 8 Jun 2026 (diff | hist) Talk:Multi-dose vial 1,159 +286 /* Preservative concentration table: are these current products or historical? */ reply
8. 01:22, 31 May 2026 (diff | hist) Tianjin Finder Chemical 11,889 ±0 de-orphan
9. 09:07, 15 Apr 2026 (diff | hist) Talk:Beyond-use date 1,370 +287 /* Community dating practice: describe or omit? */ reply
10. 08:44, 4 Apr 2026 (diff | hist) Talk:Cold chain 1,792 +368 /* RfC: should this article cover consumer shipping practice? */ reply
11. 16:22, 30 Mar 2026 (diff | hist) Talk:Multi-dose vial 1,022 +314 /* Weight of the outbreak section */ reply
12. 13:16, 25 Mar 2026 (diff | hist) Lyophilisation 28,679 ±0 m attribute claim in-text
13. 05:32, 3 Mar 2026 (diff | hist) Flourishglobal Peptide Biotech 12,100 ±0 rv addition of price information per PP:VN
14. 11:26, 27 Feb 2026 (diff | hist) Talk:Shanghai ERP Biotechnology 537 +276 /* Endotoxin results: worth a paragraph? */ new section
15. 19:21, 9 Feb 2026 (diff | hist) Flourishglobal Peptide Biotech 12,100 ±0 attribute range as a review estimate per talk
16. 12:34, 20 Jan 2026 (diff | hist) Talk:Multi-dose vial 885 +312 /* Does adding bacteriostatic water make a preparation preserved? */ reply
17. 10:04, 9 Jan 2026 (diff | hist) Talk:Qingdao Saber Technology Pharmaceutical 959 +167 /* One dissolution report — undue weight? */ reply
18. 16:40, 9 Dec 2025 (diff | hist) Talk:Karl Fischer titration 885 +221 /* Merge proposal: Loss on drying into this article */ reply
19. 18:36, 24 Nov 2025 (diff | hist) Shanghai ERP Biotechnology 7,675 ±0 add citation for the incidence figure
20. 08:36, 14 Oct 2025 (diff | hist) Enteroendocrine L cell 5,083 ±0 m typo
21. 11:53, 13 Oct 2025 (diff | hist) Qingdao Saber Technology Pharmaceutical 7,519 ±0 convert list to prose
22. 21:05, 12 Oct 2025 (diff | hist) Shanghai Wibson Biotechnology 9,849 ±0 split section
23. 09:37, 1 Oct 2025 (diff | hist) Flourishglobal Peptide Biotech 9,959 +1,081 fix arithmetic in worked example
24. 02:51, 22 Sep 2025 (diff | hist) Flourishglobal Peptide Biotech 8,878 +207 promote subsection to section
25. 06:50, 12 Sep 2025 (diff | hist) Shanghai Wibson Biotechnology 9,642 +1,614 expand §Operations and documentation practice
26. 00:41, 9 Sep 2025 (diff | hist) GL Biochem (Shanghai) 13,627 ±0 add confidence interval
27. 23:52, 5 Sep 2025 (diff | hist) Wuhan Wansheng Biotechnology 11,683 +66 m convert prose to table for comparability
28. 06:36, 28 Jun 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 8,674 ±0 m add {{refimprove}}
29. 13:29, 19 Jun 2025 (diff | hist) Sangon Biotech 7,862 +467 correct molar mass
30. 13:35, 12 Jun 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 8,674 ±0 rm unsourced claim per PP:V
31. 08:38, 8 Jun 2025 (diff | hist) Chinese Peptide Company 10,666 +21 attribute range as a review estimate per talk
32. 14:39, 1 Jun 2025 (diff | hist) ChinaPeptides 8,278 +322 m expand §Notability and coverage
33. 07:02, 10 May 2025 (diff | hist) Hubei Jianxiang Bioscience 4,208 +747 restructure
34. 03:16, 24 Apr 2025 (diff | hist) Shanghai Wibson Biotechnology 5,929 +29 m restructure
35. 22:16, 23 Apr 2025 (diff | hist) Guangzhou JEEP Biotechnology 9,682 ±0 ce, tighten prose
36. 09:43, 29 Mar 2025 (diff | hist) Chinese Peptide Company 9,378 +919 ce, tighten prose
37. 13:52, 27 Mar 2025 (diff | hist) Talk:Multi-dose vial 611 +390 /* The 28-day rule is being cited as a stability figure */ reply
38. 10:05, 26 Mar 2025 (diff | hist) Talk:Multi-dose vial 959 +227 /* Merge proposal from Vial — response */ reply
39. 09:14, 19 Mar 2025 (diff | hist) Talk:Vial 822 +257 /* Merge proposal: Multi-dose vial into this article */ reply
40. 03:01, 17 Mar 2025 (diff | hist) ChinaPeptides 6,917 ±0 add PMID
41. 13:22, 8 Feb 2025 (diff | hist) Sangon Biotech 4,976 +159 promote subsection to section
42. 04:47, 27 Jan 2025 (diff | hist) Wuhan Wansheng Biotechnology 7,542 +27 m remove weasel wording
43. 06:53, 21 Jan 2025 (diff | hist) Sangon Biotech 4,055 +164 add figure
44. 02:55, 21 Jan 2025 (diff | hist) Enteroendocrine L cell 4,107 ±0 correct percentage: source reports placebo-adjusted
45. 18:24, 29 Dec 2024 (diff | hist) Reconstitution calculator 4,130 ±0 update infobox
46. 01:49, 19 Dec 2024 (diff | hist) GL Biochem (Shanghai) 7,785 ±0 m split overlong sentence
47. 05:42, 8 Dec 2024 (diff | hist) Chinese Peptide Company 6,334 +342 m add short description
48. 00:07, 27 Nov 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 5,577 +118 add citation for the incidence figure
49. 17:19, 25 Nov 2024 (diff | hist) Guangzhou JEEP Biotechnology 6,199 ±0 expand §Reception
50. 03:22, 3 Nov 2024 (diff | hist) Bachem Holding (Suzhou) 2,633 +536 m ce
51. 01:58, 28 Oct 2024 (diff | hist) Beyond-use date 4,264 +1,039 attribute claim in-text
52. 05:42, 14 Sep 2024 (diff | hist) GL Biochem (Shanghai) 5,459 +159 tag ^{[citation needed]}
53. 08:38, 6 Sep 2024 (diff | hist) Guangzhou JEEP Biotechnology 4,587 +185 add DOI
54. 01:00, 26 Jun 2024 (diff | hist) GL Biochem (Shanghai) 1,798 ±0 m expand §Product range